Ziccum AB (publ) share issue oversubscribed before listing on Spotlight

09 October, 2018

CEO Göran Conradson’s statement:

"It’s gratifying that the new issue has been fully subscribed and we can now begin speeding up the development of our projects. We believe that Ziccum’s unique technology has significant medical and commercial potential, and I look forward to keeping investors informed as our projects move forward and approach market. I’d like to offer a warm welcome to all Ziccum AB’s new owners!"

Ziccum was founded as a spin-out from Inhalation Sciences, which was successfully noted on Spotlight (formerly Aktietorget) in September 2017. Ziccum"s vision is to enable the delivery of safe and effective drugs to all environments worldwide, minimizing costly and impractical fridge and freezer transport and storage.

Advisors

Fredersen Advokatbyrå AB has acted as legal adviser in connection with the issue. Aqurat Fondkommission AB has acted as the issuer.


For more information about Ziccum, please contact: 

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99


About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company"s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.